Organovo Holdings, Inc. (ONVO) Holdings Increased by Voya Investment Management LLC
Voya Investment Management LLC grew its holdings in shares of Organovo Holdings, Inc. (NASDAQ:ONVO) by 18.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,032 shares of the medical research company’s stock after acquiring an additional 8,225 shares during the period. Voya Investment Management LLC’s holdings in Organovo Holdings were worth $137,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of ONVO. Bank of America Corp DE grew its holdings in Organovo Holdings by 34.0% during the 1st quarter. Bank of America Corp DE now owns 35,311 shares of the medical research company’s stock worth $113,000 after acquiring an additional 8,967 shares during the period. American International Group Inc. grew its holdings in Organovo Holdings by 7.9% during the 1st quarter. American International Group Inc. now owns 53,431 shares of the medical research company’s stock worth $170,000 after acquiring an additional 3,920 shares during the period. State of Wisconsin Investment Board acquired a new stake in Organovo Holdings during the 2nd quarter worth about $196,000. Metropolitan Life Insurance Co. NY grew its holdings in Organovo Holdings by 15.0% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 68,487 shares of the medical research company’s stock worth $218,000 after acquiring an additional 8,958 shares during the period. Finally, Trent Capital Management Inc. NC acquired a new stake in Organovo Holdings during the 2nd quarter worth about $222,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.
Organovo Holdings, Inc. (NASDAQ ONVO) opened at $1.51 on Thursday. Organovo Holdings, Inc. has a 1 year low of $1.32 and a 1 year high of $4.08.
Organovo Holdings (NASDAQ:ONVO) last released its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $1.36 million for the quarter, compared to analysts’ expectations of $1.38 million. Organovo Holdings had a negative net margin of 923.89% and a negative return on equity of 65.63%. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. equities analysts predict that Organovo Holdings, Inc. will post -0.36 earnings per share for the current year.
ONVO has been the subject of a number of recent analyst reports. Jefferies Group LLC reiterated a “buy” rating and set a $4.00 price target on shares of Organovo Holdings in a report on Thursday, July 27th. ValuEngine downgraded Organovo Holdings from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Citigroup Inc. downgraded Organovo Holdings to a “market perform” rating in a report on Friday, November 10th. BTIG Research reiterated a “buy” rating and set a $3.00 price target on shares of Organovo Holdings in a report on Thursday, November 16th. Finally, Raymond James Financial, Inc. downgraded Organovo Holdings from an “outperform” rating to a “market perform” rating and set a $5.00 price target for the company. in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $3.60.
Organovo Holdings Company Profile
Receive News & Ratings for Organovo Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.